Literature DB >> 1433187

A general method for the preparation of internally quenched fluorogenic protease substrates using solid-phase peptide synthesis.

L L Maggiora1, C W Smith, Z Y Zhang.   

Abstract

A general scheme for obtaining a fluorescent donor/acceptor peptide substrate via solid-phase synthesis methodology is presented. The key feature of this method is the design of a glutamic acid derivative that has been modified on the carboxyl side chain with a 5-[(2'-aminoethyl)-amino]naphthelenesulfonic acid (EDANS) to create a fluorescent donor moiety that can be incorporated near the C-terminus of the peptide substrate. The corresponding fluorescent acceptor group containing a 4-[[4-(dimethylamino)phenyl]azo]benzoic acid (DABCYL) can then be attached to the resin-bound peptide at the N-terminus while all side-chain groups are still fully protected. Substrates for renin and HIV proteinase are synthesized as examples.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1433187     DOI: 10.1021/jm00099a001

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Using fluorogenic peptide substrates to assay matrix metalloproteinases.

Authors:  G B Fields
Journal:  Methods Mol Biol       Date:  2001

Review 2.  Bright ideas for chemical biology.

Authors:  Luke D Lavis; Ronald T Raines
Journal:  ACS Chem Biol       Date:  2008-03-20       Impact factor: 5.100

3.  Portion-mixing peptide libraries of quenched fluorogenic substrates for complete subsite mapping of endoprotease specificity.

Authors:  M Meldal; I Svendsen; K Breddam; F I Auzanneau
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

4.  Clavanin A improves outcome of complications from different bacterial infections.

Authors:  Osmar N Silva; Isabel C M Fensterseifer; Elaine A Rodrigues; Hortência H S Holanda; Natasha R F Novaes; Junia P A Cunha; Taia M B Rezende; Kelly G Magalhães; Susana E Moreno; Márcio S Jerônimo; Anamélia L Bocca; Octavio L Franco
Journal:  Antimicrob Agents Chemother       Date:  2014-12-29       Impact factor: 5.191

5.  Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.

Authors:  Lili Chen; Chunshan Gui; Xiaomin Luo; Qingang Yang; Stephan Günther; Elke Scandella; Christian Drosten; Donglu Bai; Xichang He; Burkhard Ludewig; Jing Chen; Haibin Luo; Yiming Yang; Yifu Yang; Jianping Zou; Volker Thiel; Kaixian Chen; Jianhua Shen; Xu Shen; Hualiang Jiang
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  An anti-infective synthetic peptide with dual antimicrobial and immunomodulatory activities.

Authors:  O N Silva; C de la Fuente-Núñez; E F Haney; I C M Fensterseifer; S M Ribeiro; W F Porto; P Brown; C Faria-Junior; T M B Rezende; S E Moreno; T K Lu; R E W Hancock; O L Franco
Journal:  Sci Rep       Date:  2016-11-02       Impact factor: 4.379

7.  Highly sensitive and adaptable fluorescence-quenched pair discloses the substrate specificity profiles in diverse protease families.

Authors:  Marcin Poreba; Aleksandra Szalek; Wioletta Rut; Paulina Kasperkiewicz; Izabela Rutkowska-Wlodarczyk; Scott J Snipas; Yoshifumi Itoh; Dusan Turk; Boris Turk; Christopher M Overall; Leszek Kaczmarek; Guy S Salvesen; Marcin Drag
Journal:  Sci Rep       Date:  2017-02-23       Impact factor: 4.379

8.  Enzymatic activity characterization of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer technique.

Authors:  Shuai Chen; Li-li Chen; Hai-bin Luo; Tao Sun; Jing Chen; Fei Ye; Jian-hua Cai; Jing-kang Shen; Xu Shen; Hua-liang Jiang
Journal:  Acta Pharmacol Sin       Date:  2005-01       Impact factor: 6.150

9.  Evaluation of the biotechnological potential of peptide Cupiennin 1a and analogs.

Authors:  Rayssa Oliveira Araújo; Michel Lopes Leite; Thais Tavares Baraviera Dutra; Nicolau Brito da Cunha; Taia Maria Berto Rezende; Marcelo Henrique Soller Ramada; Simoni Campos Dias
Journal:  Front Microbiol       Date:  2022-08-18       Impact factor: 6.064

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.